ArticleCancer communications (London, England)2024

Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial.

Jing Zuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.